- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01147029
GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy
A Cancer Research UK Phase I Trial of 4-(N-(S-Glutathionylacetyl) Amino) Phenylarsenoxide (GSAO) Given as Daily Intravenous Infusions on Days 1-5 and 8-12 of a 21-Day Cycle, to Patients With Advanced Solid Tumors
RATIONALE: GSAO may stop the growth of solid tumors by blocking blood flow to the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of GSAO in treating patients with advanced solid tumors that have not responded to therapy.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
OBJECTIVES:
Primary
- To determine the maximum-tolerated dose and recommended phase II dose of angiogenesis inhibitor GSAO in patients with advanced, refractory solid tumors.
- To assess the safety and toxicity profile and dose-limiting toxicity of this drug in these patients.
Secondary
- To determine the pharmacokinetics of this drug in these patients.
- To determine the pharmacodynamics of this drug in these patients.
- To determine possible anti-tumor activity in patients treatment with this drug.
Tertiary
- To further determine the pharmacodynamics of this drug in these patients.
OUTLINE: This is a multicenter, dose-escalation study.
Patients receive angiogenesis inhibitor GSAO IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients showing clinical benefit (i.e., stable disease, partial response, or complete response) may receive 6 additional courses of treatment. Patients receive angiogenesis inhibitor GSAO IV over 1 hour on day -7 to obtain pharmacokinetics information of a single IV dose of the drug.
Patients also undergo dynamic contrast-enhanced magnetic-resonance imaging (DCE-MRI) prior to, during, and after study to determine blood flow parameters.
Blood samples are collected periodically for pharmacokinetic, pharmacodynamic, and biomarker studies.
After completion of study treatment, patients are followed up for 28 days and then once a month thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
England
-
Manchester, England, Royaume-Uni, M20 4BX
- Christie Hospital
-
Oxford, England, Royaume-Uni, OX3 7LJ
- Churchill Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Histologically confirmed advanced solid tumor
- Refractory to conventional treatment or for which no conventional therapy exists
- Disease assessable by DCE-MRI and should be of a size that can be adequately assessed by these techniques
- No known primary brain tumors or brain metastases
PATIENT CHARACTERISTICS:
- WHO performance status 0-1
- Life expectancy ≥ 12 weeks
- Hemoglobin ≥ 9.0 g/dL
- Platelet count ≥ 100 x 10^9/L
- Neutrophil count ≥ 1.5 x 10^9/L
- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT and AST ≤ 2.5 times ULN
- Creatinine clearance ≥ 50 mL/min (uncorrected value)
- Serum potassium and magnesium normal
- No proteinuria > grade 1 either on 24-hour urine or on 2 consecutive dipsticks taken no less than 1 week apart
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception 4 weeks prior to, during, and for 6 months after completion of study therapy
- Not at high medical risk due to non-malignant systemic disease, including active uncontrolled infection
- No serologically positive hepatitis B, hepatitis C, or HIV
- No concurrent congestive heart failure or prior NYHA class III-IV cardiac disease
None of the following medical conditions:
- Angina (stable or severe, even if well controlled on medication)
- Myocardial infarction in the past 2 months by ECG
- Congestive cardiac failure
- Arrhythmias, including any condition associated with QTc prolongation (e.g., Lange-Neilson syndrome or Romano Ward syndrome)
- Evidence of ischemia
- QTc > 480 msec
- Other clinically significant abnormalities
- No uncontrolled hypertension (defined as BP consistently greater than 160/100 mm Hg irrespective of medication)
- No other condition that, in the opinion of the investigator, would not make the patient a good candidate for this clinical trial
- No pacemakers
- No metal fragments in the eyes or shrapnel or bullet injuries
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from all prior treatments (except for alopecia or certain grade 1 toxicities which, in the opinion of the investigator and Cancer Research UK, should not exclude the patient)
- At least 4 weeks since prior radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy, or chemotherapy (6 weeks for nitrosoureas and mitomycin C)
- At least 1 week since prior and no concurrent shellfish
- At least 6 weeks since prior major surgery (including thoracic and/or abdominal surgery) and recovered
- Concurrent luteinizing-hormone releasing-hormone (LHRH) analogues allowed for patients with castration-refractory prostate cancer provided the prostate-specific antigen level is rising
- No prior heart or brain surgery
- No concurrent drug known to prolong the QTc interval
- No concurrent warfarin (1 mg for maintenance of a Hickman line is acceptable) or heparin (flushing of arterial lines, if necessary, is acceptable)
- No concurrent naproxen (other NSAIDs are acceptable)
No concurrent prophylactic use of antiemetics during the first treatment
- Domperidone and lorazepam must not be used as antiemetics
No other concurrent anticancer therapy or investigational drugs
- Concurrent bisphosphonates allowed
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
---|
Toxicité limitant la dose
|
Causality of each adverse event and grading severity according to NCI CTCAE Version 3.0
|
Mesures de résultats secondaires
Mesure des résultats |
---|
Relationship between pharmacokinetics and toxicity and/or markers of efficacy
|
Changes in microvascular function using DCE-MRI
|
Plasma and tumor levels of angiogenic factors and apoptosis markers
|
Response (stable disease, partial response, or complete response) as determined by RECIST criteria
|
Circulating endothelial cells and circulating endothelial progenitor cells as a marker of inhibition of angiogenesis
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Gordon Jayson, MD, The Christie NHS Foundation Trust
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000675271
- CRUK-PH1-109
- EUDRACT-2006-002326-34
- CTA-21106-0222-001
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur étude pharmacologique
-
Apple Inc.Stanford UniversityComplétéFibrillation auriculaire | Arythmies cardiaques | Flutter auriculaireÉtats-Unis
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCRecrutementMaladies du cerveau | Troubles du mouvement | Maladies neurodégénératives | Paralysie supranucléaire progressivePays-Bas
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCRecrutementMaladies du cerveau | Maladies du système nerveux central | Maladies du système nerveux | Maladie de Parkinson | Troubles parkinsoniens | Maladies des noyaux gris centraux | Troubles du mouvement | Maladies neurodégénérativesPays-Bas
-
Radicle ScienceComplétéLa dépression | La douleur | Dormir | AnxiétéÉtats-Unis
-
Radicle ScienceComplété
-
Radicle ScienceComplété
-
Digisight Technologies, Inc.InconnueLa rétinopathie diabétique | Dégénérescence maculaire liée à l'âge | MétamorphopsieÉtats-Unis
-
St. Joseph's Healthcare HamiltonSuspendu
-
Seno Medical Instruments Inc.Complété